Track topics on Twitter Track topics that are important to you
Trimeris, Inc. (Nasdaq: TRMS) is a biopharmaceutical company engaged in the commercialization of therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. FUZEONÂ®, approved in the U.S., Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about Trimeris, please visit the Company's website at http://www.trimeris.com.
Top stories on October 6th, 2009: Sanofi launch generic of their own drug Plavix Trimeris sold to Arigene for $81M Sandoz CEO: 10 new drugs a year in Japan CBR Pharma Insights on ‘lifecycle...
Trimeris, Inc. (Nasdaq: TRMS) is a biopharmaceutical company engaged in the commercialization of therapeutic agents for the treatment of viral disease. The core technology platfor...
Based in Morrisville, North Carolina, Trimeris was founded in 1993 by leading researchers in the study of the human immunodeficiency virus (HIV). Their work in the early 1990s led to a breakthrough in...
We have published hundreds of Trimeris, Inc. news stories on BioPortfolio along with dozens of Trimeris, Inc. Clinical Trials and PubMed Articles about Trimeris, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Trimeris, Inc. Companies in our database. You can also find out about relevant Trimeris, Inc. Drugs and Medications on this site too.